Composition for treating osteoporosis and application thereof

By combining the exosomes of mesenchymal stem cell that can express OPG protein and IL-8 protein simultaneously with Eucommia ulmoides extract, the safety and effectiveness of existing drugs have been solved, and the bone resistance to bending is significantly improved and bone density, providing a safe and effective treatment for osteoporosis.

CN119033838AInactive Publication Date: 2024-11-29ZHONGKE CELL TECH (GUANGZHOU) CO LTD
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
CN202411547394.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-11-01
Publication Date
2024-11-29
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

The existing drugs used to treat osteoporosis have safety and effectiveness issues, which cannot effectively reduce the risk of fractures and may cause adverse reactions to other drugs.

Method used

Mesenchymal stem cell exosomes that can express OPG protein and IL-8 protein simultaneously are combined with Eucommia ulmoide extraction liquid to improve bone bending ability, bone compressive stress and bone density.

Benefits of technology

Significantly improves bone bending ability, bone compressive stress and bone density, providing a safe and effective composition for treating osteoporosis with synergistic effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119033838A_ABST
    Figure CN119033838A_ABST
Patent Text Reader

Abstract

The invention provides a composition for treating osteoporosis and application of the composition. The composition contains a mesenchymal stem cell exosome and a eucommia ulmoides extracting solution in a dosage ratio of (14-16) mg: (8-12) mL, the mesenchymal stem cell exosome is a mesenchymal stem cell exosome capable of simultaneously expressing an OPG protein and an IL-8 protein; the amino acid sequence of the OPG protein is as shown in SEQ ID NO: 1, and the amino acid sequence of the IL-8 protein is as shown in SEQ ID NO: 2; every 1mL of the eucommia ulmoides extracting solution contains 0.8-1.2 g of eucommia ulmoides extract. The invention finds that the bone bending resistance, the bone pressure stress, the bone density and the tissue mineral density can be remarkably improved by compounding the mesenchymal stem cell exosome capable of simultaneously expressing the OPG protein and the IL-8 protein with the eucommia ulmoides extracting solution, so that the osteoporosis can be effectively treated.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of medical technology, and more specifically, relates to a composition for treating osteoporosis and its application. Background Art

[0002] Osteoporosis is a systemic bone disease caused by a variety of reasons, with bone density and bone quality as the main characteristics. Osteoporosis patients' bone bending resistance, bone compressive stress, bone density, tissue mineral density, etc. will be significantly reduced, resulting in a significant decrease in bone strength, bone toughness and bone recovery ability. They are prone to fractures, need to stay in bed for a long time, and may even lose the ability to live independently, or develop pneumonia, urinary tract infection, bedsores, venous thrombosis and other diseases.

[0003] At present, the drugs used to treat osteoporosis mainly include bone mineralization promoters, bone resorption inhibitors and bone formation promoters. Bone mineralization promoters mainly include calcium, vitamin D, calcium / vitamin D combined supplements, etc., but these bone mineralization promoters cannot reduce the risk of fractures. Bone resorption inhibitors mainly include bisphosphonates, calcitonin, estrogen, selective estrogen receptor modulators, etc., but excessive bone resorption inhibitors can easily lead to accumulation of bone microcracks and decreased bone strength, which may eventually cause frozen bones. Bone formation promoters mainly include fluorine preparations, parathyroid hormone analogs, androgens and protein anabolic agents, etc., but fluorine preparations are prone to calcification defects, parathyroid hormone analogs have the risk of inducing osteosarcoma, androgens and protein anabolic agents have adverse drug reactions such as masculinization, increased low-density lipoprotein and affecting liver function.

[0004] Therefore, it is urgent to find a safe and effective drug for the treatment of osteoporosis, which is very important for osteoporosis patients. Summary of the invention

[0005] The present invention aims to provide a composition for treating osteoporosis by compounding mesenchymal stem cell exosomes that can simultaneously express OPG protein and IL-8 protein with Eucommia ulmoides extract, and it is found that it can significantly improve bone bending resistance, bone compressive stress, bone density and tissue mineral density, thereby effectively treating osteoporosis. In addition, since OPG protein, IL-8 protein, mesenchymal stem cell exosomes and Eucommia ulmoides extract are all substances with high safety, the safety of the composition is also high, and it is suitable for preparing a safe and effective drug for treating osteoporosis.

[0006] The first object of the present invention is to provide a composition for treating osteoporosis.

[0007] The second object of the present invention is to provide the use of the above composition in the preparation of a drug for treating osteoporosis.

[0008] The third object of the present invention is to provide a drug for treating osteoporosis.

[0009] The above-mentioned purpose of the present invention is achieved through the following technical solutions: The present invention provides a composition for treating osteoporosis, the composition comprising mesenchymal stem cell exosomes and eucommia extract in a dosage ratio of 14-16 mg: 8-12 mL; the mesenchymal stem cell exosomes are mesenchymal stem cell exosomes capable of simultaneously expressing OPG protein and IL-8 protein; the amino acid sequence of the OPG protein is shown in SEQ ID NO: 1, and the amino acid sequence of the IL-8 protein is shown in SEQ ID NO: 2; each 1 mL of eucommia extract contains an extract equivalent to 0.8-1.2 g of eucommia.

[0010] The present invention combines mesenchymal stem cell exosomes that can simultaneously express OPG protein (SEQ ID NO: 1) and IL-8 protein (SEQ ID NO: 2) with Eucommia ulmoides extract, and finds that it can significantly improve bone bending resistance, bone compressive stress, bone density and tissue mineral density, thereby effectively treating osteoporosis. In addition, OPG protein, IL-8 protein and Eucommia ulmoides extract have synergistic effects in improving bone bending resistance, bone compressive stress and tissue mineral density, that is, they have significant synergistic effects in treating osteoporosis.

[0011] The amino acid sequence of the OPG protein is shown in SEQ ID NO: 1: MNKLLCCALVFLDISIKWTTQETFPPKYLHYDEETSHQLLCDKCPPGTYLKQHCTAKWKTVCAPCPDHYYTDSWHTSDECLYCSPVCKELQYVKQECNRTHNRVCECKEGRYLEIEFCLKHRSCPPGFGVVQAGTPERNTVCKRCPDGFFSNETSSKAPCRKHTNCSVFGLLLTQKGNATHDNICSGNSESTQK.

[0012] The amino acid sequence of IL-8 protein is shown in SEQ ID NO: 2: KKPGRPSHCVNDFSWPGSLQPSISSSVKVQLPVLELRSVHRHSKPPPQFIKTELRGPHRQQKLCKALMEELSGPRKTVQLWKFLEGIHKNSLCGSKNVKASEF KQLLTLHYCVSVVVAMQYDSWKFFSTMNFFITMISRILIVKYFINLQNNKIFIGFPRLHGNINSKGQAKYPLFGIEGLRMFEAHIKDGNKFPSNLWKSGFFCI ATSLLQDPPSPPLPWFPLFKWKVLHHLPHSCCGHVSTLFFSHNYFSVTLTFIICIYKHYLQEFKNRMNLIEVIKCYSIYYFRLNDFIINFIRVIKNKIGYSIHF KQNNFSISIILSEFNLTISLTPSCHCAVGSACIGIMLEIKTQNSSQSNLAGKLVLCKIYNIFKAFKYKFIFNFDVFCALNFFLFDCMNIKKYHLIFCQSKKK.

[0013] Preferably, the dosage ratio of the mesenchymal stem cell exosomes to the Eucommia ulmoides extract is 15 mg:10 mL.

[0014] Preferably, the mesenchymal stem cells are umbilical cord mesenchymal stem cells.

[0015] Preferably, the preparation method of the Eucommia ulmoides extract is: soaking the Eucommia ulmoides in water for 10 to 14 hours, heating and extracting at 95 to 100°C for 5.4 to 6.6 hours, filtering, and concentrating the filtrate.

[0016] Further preferably, the ratio of water to Eucommia ulmoides is 30-36 mL:1 g, most preferably 33 mL:1 g.

[0017] Further preferably, the preparation method of the Eucommia extract is: adding water to the Eucommia for the first time, soaking for 10 to 14 hours (most preferably 12 hours), then heating at 95 to 100°C (most preferably 100°C) for 1.8 to 2.2 hours (most preferably 2 hours), and filtering for the first time; adding water to the filter residue obtained by the first filtration for the second time, heating at 95 to 100°C (most preferably 100°C) for 1.8 to 2.2 hours (most preferably 2 hours), and filtering for the second time; then adding water to the filter residue obtained by the second filtration for the third time, heating at 95 to 100°C (most preferably 100°C) for 1.8 to 2.2 hours (most preferably 2 hours), and filtering for the third time; combining the three filtrates and concentrating.

[0018] More preferably, the ratio of the amount of water added for the first time to the amount of Eucommia ulmoides is 12-14 mL:1 g, and most preferably 13 mL:1 g.

[0019] More preferably, the ratio of the amount of water added for the second time to the amount of Eucommia ulmoides is 9-11 mL:1 g, and most preferably is 10 mL:1 g.

[0020] More preferably, the ratio of the amount of water added for the third time to the amount of Eucommia ulmoides is 9-11 mL:1 g, and most preferably is 10 mL:1 g.

[0021] More preferably, the concentration is to concentrate until each 1 mL of eucommia extract contains an extract equivalent to 0.8-1.2 g of eucommia, and most preferably, to concentrate until each 1 mL of eucommia extract contains an extract equivalent to 1 g of eucommia.

[0022] The mesenchymal stem cell exosomes capable of simultaneously expressing OPG protein and IL-8 protein can be synthesized by common means in the art, such as: firstly synthesizing the amino acid sequences of OPG protein and IL-8 protein respectively by molecular biological means, and constructing the pSin-EF2-OPG-IL8 recombinant plasmid, and then culturing the mesenchymal stem cells after transfecting the recombinant plasmid with lentivirus, and separating the mesenchymal stem cell exosomes capable of simultaneously expressing OPG protein and IL-8 protein. Optionally, the culturing is culturing at 35-39°C for 70-74 hours (most preferably culturing at 37°C for 72 hours).

[0023] Preferably, the composition for treating osteoporosis is obtained by uniformly mixing the raw materials.

[0024] More preferably, after the mixing, the pH is adjusted to 5.8-6.2, such as by using HCl.

[0025] The above-mentioned composition for treating osteoporosis can significantly improve the anti-bending ability of bones, bone compressive stress, bone density and tissue mineral density, thereby effectively treating osteoporosis. Therefore, the use of the above-mentioned composition in the preparation of a medicament for treating osteoporosis should also be within the scope of protection of the present invention. Optionally, the osteoporosis is osteoporosis in middle-aged and elderly patients. It should be understood that middle-aged and elderly refer to people aged 45 and above.

[0026] Based on this, the present invention also provides a drug for treating osteoporosis, wherein each 1000 mL of the drug comprises the following components: 14-16 mg of mesenchymal stem cell exosomes, 8-12 mL of Eucommia ulmoides extract, 25-35 g of a detergent, 20-30 g of a moisturizer, and the remainder is water; The mesenchymal stem cell exosomes are mesenchymal stem cell exosomes that can simultaneously express OPG protein and IL-8 protein; each 1 mL of eucommia extract contains an extract equivalent to 0.8 to 1.2 g of eucommia.

[0027] Preferably, each 1000 mL of the drug contains the following components: 14-16 mg of mesenchymal stem cell exosomes, 8-12 mL of Eucommia ulmoides extract, 25-35 g of a detergent, 8-10 g of a preservative, 20-30 g of a moisturizer, and the balance is water.

[0028] Preferably, each 1000 mL of the drug contains the following components: 14-16 mg of mesenchymal stem cell exosomes, 8-12 mL of Eucommia ulmoides extract, 25-35 g of a detergent, 18-22 g of a suspending agent, 20-30 g of a moisturizer, and the balance is water.

[0029] Preferably, each 1000 mL of the drug contains the following components: 14-16 mg of mesenchymal stem cell exosomes, 8-12 mL of Eucommia ulmoides extract, 25-35 g of a detergent, 20-30 g of a moisturizer, 6-8 g of a cooling agent, and the remainder is water.

[0030] Preferably, each 1000 mL of the drug contains the following components: 14-16 mg of mesenchymal stem cell exosomes, 8-12 mL of Eucommia ulmoides extract, 25-35 g of detergent, 8-10 g of preservative, 18-22 g of suspending agent, 20-30 g of humectant, 6-8 g of cooling agent, and the balance is water.

[0031] Further preferably, each 1000 mL of the drug contains the following components: 15 mg of mesenchymal stem cell exosomes, 10 mL of Eucommia ulmoides extract, 30 g of detergent, 9 g of preservative, 20 g of suspending agent, 25 g of humectant, 7 g of cooling agent, and the balance is water; the mesenchymal stem cell exosomes are mesenchymal stem cell exosomes that can simultaneously express OPG protein and IL-8 protein; each 1 mL of Eucommia ulmoides extract contains an extract equivalent to 1 g of Eucommia ulmoides.

[0032] Preferably, the cleaning agent is sodium chloride.

[0033] Preferably, the preservative is disodium edetate and / or benzalkonium chloride, such as disodium edetate and benzalkonium chloride in a mass ratio of 7.8-9:0.2-1, and most preferably disodium edetate and benzalkonium chloride in a mass ratio of 8.5:0.5.

[0034] Preferably, the suspending agent is microcrystalline cellulose-sodium carboxymethyl cellulose and / or polysorbate, such as microcrystalline cellulose-sodium carboxymethyl cellulose and polysorbate in a mass ratio of 14-16:4-6, and most preferably microcrystalline cellulose-sodium carboxymethyl cellulose and polysorbate in a mass ratio of 15:5.

[0035] Preferably, the humectant is glycerin.

[0036] Preferably, the cooling agent is eucalyptol.

[0037] Preferably, the dosage form of the drug is one or more of nasal spray, injection, and oral preparation. When the dosage form of the drug is nasal spray, the therapeutic effect is better, the patient's compliance is also higher, and compared with traditional nasal sprays, the drug of the present invention will not affect the nasal microenvironment, will not cause some adverse reactions due to drug accumulation in the nasal cavity, and can achieve the purpose of convenient treatment anytime, anywhere.

[0038] As a preferred implementation scheme, the 1000 mL drug for treating osteoporosis comprises the following components: 14-16 mg of mesenchymal stem cell exosomes, 8-12 mL of Eucommia ulmoides extract, 25-35 g of sodium chloride, 8-10 g of preservative (disodium edetate and benzalkonium chloride in a mass ratio of 7.8-9:0.2-1), 18-22 g of suspending agent (microcrystalline cellulose-sodium carboxymethyl cellulose and polysorbate in a mass ratio of 14-16:4-6), 20-30 g of glycerol, 6-8 g of eucalyptol, and the balance is water; the mesenchymal stem cell exosomes are mesenchymal stem cell exosomes that can simultaneously express OPG protein and IL-8 protein; each 1 mL of Eucommia ulmoides extract contains an extract equivalent to 0.8-1.2 g of Eucommia ulmoides.

[0039] Most preferably, the 1000 mL drug for treating osteoporosis comprises the following components: 15 mg of mesenchymal stem cell exosomes, 10 mL of Eucommia ulmoides extract, 30 g of sodium chloride, 9 g of preservative (disodium edetate and benzalkonium chloride in a mass ratio of 8.5:0.5), 20 g of suspending agent (microcrystalline cellulose-sodium carboxymethyl cellulose and polysorbate in a mass ratio of 15:5), 25 g of glycerol, 7 g of eucalyptol, and the balance is water; the mesenchymal stem cell exosomes are mesenchymal stem cell exosomes that can simultaneously express OPG protein and IL-8 protein; each 1 mL of Eucommia ulmoides extract contains an extract equivalent to 1 g of Eucommia ulmoides.

[0040] In addition, the above-mentioned drug for treating osteoporosis can be prepared by the following method: first add mesenchymal stem cell exosomes, a detergent, an optional preservative, an optional polysorbate, a humectant, and an optional cooling agent into water, mix well, then add optional microcrystalline cellulose-sodium carboxymethyl cellulose, mix well, and finally add eucommia extract and mix well to obtain the drug.

[0041] As a preferred implementation scheme, the above-mentioned drug for treating osteoporosis can be prepared by the following method: first, mesenchymal stem cell exosomes, sodium chloride, disodium edetate, benzalkonium chloride, polysorbate, glycerol, and eucalyptus are added to water, mixed, then microcrystalline cellulose-sodium carboxymethyl cellulose is added, mixed, and finally, Eucommia ulmoides extract is added and mixed to obtain the drug.

[0042] Preferably, the pH of the drug is 5.8 to 6.2, such as adjusted with HCl.

[0043] Preferably, the drug is sterilized, such as by filtering with a 0.4-0.5 μm filter membrane.

[0044] The present invention has the following beneficial effects: 1. The present invention combines mesenchymal stem cell exosomes that can simultaneously express OPG protein and IL-8 protein with Eucommia extract to obtain a composition that can effectively treat osteoporosis. In addition, OPG protein, IL-8 protein and Eucommia extract have synergistic effects in improving bone bending resistance, bone compressive stress and tissue mineral density, that is, they have significant synergistic effects in treating osteoporosis.

[0045] 2. In the composition for treating osteoporosis of the present invention, OPG protein, IL-8 protein, mesenchymal stem cell exosomes and Eucommia ulmoides extract are all substances with relatively high safety, so the safety of the composition is also relatively high, and it is suitable for preparing a safe and effective drug for treating osteoporosis. BRIEF DESCRIPTION OF THE DRAWINGS

[0046] Figure 1 This is the map of the pSin-EF2-OPG-IL8 recombinant plasmid.

[0047] Figure 2 This is the map of the pSin-EF2-OPG recombinant plasmid.

[0048] Figure 3 This is the map of the pSin-EF2-IL8 recombinant plasmid. DETAILED DESCRIPTION

[0049] The present invention is further described below in conjunction with the accompanying drawings and specific examples, but the examples do not limit the present invention in any form. Unless otherwise specified, the reagents, methods and equipment used in the present invention are conventional reagents, methods and equipment in the art.

[0050] Unless otherwise specified, the reagents and materials used in the following examples are commercially available.

[0051] Example 1 Construction of recombinant plasmid 1. Construction of recombinant plasmid pSin-EF2-OPG-IL8 According to the codons preferred by human cells, after synthesizing the OPG protein with the amino acid sequence shown in SEQ ID NO:1 and the IL-8 protein with the amino acid sequence shown in SEQ ID NO:2, an IRES element sequence was added between the two proteins, a kozak sequence was introduced between the IL-8 protein and the IRES element sequence, and a BamHI site, a start codon, a kozak sequence and a tPA signal peptide with the amino acid sequence shown in SEQ ID NO:3 were introduced upstream of the gene, and a stop codon and an EcoRI site were introduced downstream of the gene. The synthesized gene fragments were thermostat-digested with BamHI and EcoRI at 4°C for 12 h, and then the gel where the digestion products were located was cut by agarose gel electrophoresis, and the target fragments were recovered using an agarose gel DNA recovery kit. The recovered product was mixed with the pSin-EF2-puro lentiviral expression vector after double digestion with BamHI and EcoRI at a molar ratio of 3:1, and then ligated with T4 DNA ligase in a PCR instrument at 16 ℃ for 12 h to construct the recombinant plasmid pSin-EF2-OPG-IL8 (map as shown in Figure 1 as shown).

[0052] The amino acid sequence of OPG protein is shown in SEQ ID NO: 1: MNKLLCCALVFLDISIKWTTQETFPPKYLHYDEETSHQLLCDKCPPGTYLKQHCTAKWKTVCAPCPDHYYTDSWHTSDECLYCSPVCKELQYVKQECNRTHNRVCECKEGRYLEIEFCLKHRSCPPGFGVVQAGTPERNTVCKRCPDGFFSNETSSKAPCRKHTNCSVFGLLLTQKGNATHDNICSGNSESTQK.

[0053] The amino acid sequence of IL-8 protein is shown in SEQ ID NO: 2: KKPGRPSHCVNDFSWPGSLQPSISSSVKVQLPVLELRSVHRHSKPPPQFIKTELRGPHRQQKLCKALMEELSGPRKTVQLWKFLEGIHKNSLCGSKNVKASEF KQLLTLHYCVSVVVAMQYDSWKFFSTMNFFITMISRILIVKYFINLQNNKIFIGFPRLHGNINSKGQAKYPLFGIEGLRMFEAHIKDGNKFPSNLWKSGFFCI ATSLLQDPPSPPLPWFPLFKWKVLHHLPHSCCGHVSTLFFSHNYFSVTLTFIICIYKHYLQEFKNRMNLIEVIKCYSIYYFRLNDFIINFIRVIKNKIGYSIHF KQNNFSISIILSEFNLTISLTPSCHCAVGSACIGIMLEIKTQNSSQSNLAGKLVLCKIYNIFKAFKYKFIFNFDVFCALNFFLFDCMNIKKYHLIFCQSKKK.

[0054] The amino acid sequence of the tPA signal peptide is shown in SEQ ID NO: 3: MDAMKRGLCCVLLLCGAVFVSP.

[0055] 2. Construction of recombinant plasmid pSin-EF2-OPG According to the codons preferred by human cells, the OPG protein with an amino acid sequence as shown in SEQ ID NO:1 was synthesized, and a BamHI site, a start codon, a kozak sequence, and a tPA signal peptide with an amino acid sequence as shown in SEQ ID NO:3 were introduced upstream of the gene, and a stop codon and an EcoRI site were introduced downstream of the gene. The synthesized gene fragment was isothermally digested with BamHI and EcoRI for 12 h at 4 °C, and then the gel where the digestion product was located was cut by agarose gel electrophoresis, and the target fragment was recovered using an agarose gel DNA recovery kit. The recovered product was mixed with the pSin-EF2-puro lentiviral expression vector after double digestion with BamHI and EcoRI at a molar ratio of 3:1, and then connected with T4 DNA ligase in a PCR instrument at 16 °C for 12 h to construct the recombinant plasmid pSin-EF2-OPG (map as shown in Figure 2 as shown).

[0056] 3. Construction of recombinant plasmid pSin-EF2-IL8 According to the codons preferred by human cells, the IL-8 protein with an amino acid sequence as shown in SEQ ID NO:2 was synthesized, and a BamHI site, a start codon, a kozak sequence, and a tPA signal peptide with an amino acid sequence as shown in SEQ ID NO:3 were introduced upstream of the gene, and a stop codon and an EcoRI site were introduced downstream of the gene. The synthesized gene fragment was isothermally digested with BamHI and EcoRI for 12 h at 4 °C, and then the gel where the digestion product was located was cut by agarose gel electrophoresis, and the target fragment was recovered using an agarose gel DNA recovery kit. The recovered product was mixed with the pSin-EF2-puro lentiviral expression vector after double digestion with BamHI and EcoRI at a molar ratio of 3:1, and then connected with T4 DNA ligase in a PCR instrument at 16 °C for 12 h, and the recombinant plasmid pSin-EF2-IL8 was constructed (map as shown in Figure 3 as shown).

[0057] Example 2 Transfection of recombinant plasmid The recombinant plasmids pSin-EF2-OPG-IL8, pSin-EF2-OPG and pSin-EF2-IL8 obtained in Example 1 were transformed into competent E. coli DH5α, and then the competent E. coli DH5α was evenly spread on the LB plate medium containing 100 μg / mL ampicillin. After the bacterial solution was completely absorbed, it was inverted and cultured at 37°C for 14 h. Six single colonies with good growth were picked up with a sterile pipette tip and inoculated into 5 mL of LB medium containing 100 μg / mL ampicillin. After shaking and culturing at 37°C and 225rpm for 12 h, plasmid DNA was extracted with a rapid plasmid mini-extraction kit, and then double-digested with BamHI and EcoRI, and the double-digested products were sent to a sequencing company for sequencing identification. The correct clones identified by sequencing were extracted using a plasmid extraction kit to obtain a large amount of recombinant plasmids pSin-EF2-OPG-IL8, pSin-EF2-OPG and pSin-EF2-IL8.

[0058] Then, the packaging plasmid psPAX2, the envelope plasmid pMD2G, and the recombinant plasmids (pSin-EF2-OPG-IL8, pSin-EF2-OPG, and pSin-EF2-IL8, respectively) were co-transfected into HEK-293T cells using Lipofiter transfection reagent. After culturing in DMEM medium at 37 °C for 8 h, the medium was replaced and cultured for 72 h. The supernatant was collected at 48 and 72 h of culture, respectively, and filtered through a 0.45 μM membrane to obtain the 48 h virus solution and the 72 h virus solution. The virus titer in the 48 h virus solution and the 72 h virus solution was detected using a lentivirus titer ELISA detection kit (Biolong) (confirm that the virus titer exceeded 106 TU / mL), and then store the 48 h virus solution and the 72 h virus solution in a -80 ℃ refrigerator.

[0059] Example 3 Acquisition and infection of umbilical cord mesenchymal stem cells Take fresh umbilical cord (there is no ethical controversy about the acquisition and processing methods), wash it with sterile saline to remove blood, cut it into 4 cm small pieces, remove the vein, capsule and 2 arteries, cut the Wharton's jelly into pieces and inoculate it into mesenchymal stem cell culture medium, place it in a 37°C, 5% CO2 cell culture incubator and culture it for 6 days. A large number of spindle cells can be seen crawling out of the tissue block. After subculture, amplification, purification and identification, it is confirmed that these spindle cells are umbilical cord mesenchymal stem cells.

[0060] Umbilical cord mesenchymal stem cells were inoculated on fresh mesenchymal stem cell culture medium, and subcultured at 37°C for 24 h. Then, the 48 h virus solution obtained in Example 2 (the volume ratio of the 48 h virus solution obtained in Example 2 to the mesenchymal stem cell culture medium was 3:1) and polybrene (Polybrene, the concentration of polybrene in the mesenchymal stem cell culture medium was 8 μg / mL) were added. After infection at 37°C for 8 h, fresh mesenchymal stem cell culture medium was replaced, and cultured at 37°C for another 12 h. Then, the 72 h virus solution obtained in Example 2 (the volume ratio of the 72 h virus solution obtained in Example 2 to the mesenchymal stem cell culture medium was 3:1) and polybrene (Polybrene, the concentration of polybrene in the mesenchymal stem cell culture medium was 8 μg / mL) were added. After infection at 37°C for 8 h, fresh mesenchymal stem cell culture medium was replaced, and cultured at 37°C for 72 h. Cells were collected at 48 and 72 h of culture for qPCR and Western blotting. Blot detection confirmed that umbilical cord mesenchymal stem cells infected with three recombinant plasmids were obtained.

[0061] Example 4 Preparation of umbilical cord mesenchymal stem cell exosomes The umbilical cord mesenchymal stem cells infected with the recombinant plasmid obtained in Example 3 were inoculated into fresh mesenchymal stem cell culture medium, cultured at 37 ° C for 72 h, and then centrifuged at 4 ° C and 1000 × g for 10 min, the cell precipitate was removed, the supernatant was centrifuged at 4 ° C and 10000 × g for 30 min, large cell debris and broken organelles were removed, the supernatant was centrifuged at 4 ° C and 100000 × g for 120 min, the precipitate was resuspended with PBS, and centrifuged again at 4 ° C and 100000 × g for 120 min. The precipitate obtained by centrifugation is the umbilical cord mesenchymal stem cell exosomes. After resuspending with physiological saline, the BCA method was used for quantification (to determine that the total protein concentration exceeds 0.25 μg / μL), and then Western Blot detection and ELISA detection were performed to confirm that the obtained umbilical cord mesenchymal stem cell exosomes can successfully express the corresponding protein.

[0062] Example 5 Preparation of Eucommia ulmoides extract Take 2 kg of Eucommia ulmoides, add water (13 times the mass of Eucommia ulmoides) to Eucommia ulmoides for the first time, soak for 12 hours, heat at 100 °C for 2 hours, and filter for the first time; add water (10 times the mass of Eucommia ulmoides) to the residue obtained by the first filtration for the second time, heat at 100 °C for 2 hours, and filter for the second time; then add water (10 times the mass of Eucommia ulmoides) to the residue obtained by the second filtration for the third time, heat at 100 °C for 2 hours, and filter for the third time. Combine the three filtrates, and finally concentrate the filtrate until each 1 mL of Eucommia ulmoides extract contains an extract equivalent to 1 g of Eucommia ulmoides, and store at 4 °C.

[0063] Example 6 Preparation of drugs and testing of their efficacy on osteoporosis 1. Experimental Grouping and Drug Administration Four-week-old SPF ovariectomized C57 mice (OPG- / -) were divided into 7 treatment groups, with 10 mice in each group, namely: OPG+IL-8 exosomes+Eucommia treatment group, OPG exosomes treatment group, IL-8 exosomes treatment group, Eucommia treatment group, OPG+IL-8 exosomes treatment group, OPG exosomes+Eucommia treatment group, and IL-8 exosomes+Eucommia treatment group.

[0064] The ingredients and preparation methods of the nasal spray used in each treatment group are as follows: 1. OPG+IL-8 exosomes+Eucommia ulmoides treatment group (1) Ingredients Mesenchymal stem cell exosomes (mesenchymal stem cell exosomes that can simultaneously express OPG protein and IL-8 protein) 15 mg, Eucommia ulmoides extract 10 mL, sodium chloride 30 g, edetate disodium 8.5 g, benzalkonium chloride 0.5 g, microcrystalline cellulose-sodium carboxymethyl cellulose 15 g, polysorbate 5 g, glycerol 25 g, eucalyptol 7 g, make up to 1000 mL with water.

[0065] (2) Preparation method First, add mesenchymal stem cell exosomes, sodium chloride, disodium edetate, benzalkonium chloride, polysorbate, glycerol, and eucalyptol into water and mix well. Then add microcrystalline cellulose-sodium carboxymethyl cellulose and mix well. Finally, add Eucommia ulmoides extract and mix well. Adjust the pH to 6 with HCl, filter and sterilize with a 0.45 μm sterile filter membrane, and put it into a sterile nasal spray bottle.

[0066] 2. OPG exosome treatment group (1) and (2) were the same as the OPG+IL-8 exosomes+Eucommia treatment group, except that the mesenchymal stem cell exosomes used were mesenchymal stem cell exosomes that could express OPG protein, and the Eucommia extract was replaced with an equal volume of water.

[0067] 3. IL-8 exosome treatment group (1) and (2) were the same as the OPG+IL-8 exosomes+Eucommia treatment group, except that the mesenchymal stem cell exosomes used were mesenchymal stem cell exosomes that could express IL-8 protein, and the Eucommia extract was replaced with an equal volume of water.

[0068] 4. Eucommia ulmoides treatment group (1) and (2) were the same as the OPG+IL-8 exosomes+Eucommia ulmoides treatment group, except that the MSC exosomes were replaced with an equal volume of normal saline.

[0069] 5. OPG+IL-8 exosome treatment group (1) and (2) were the same as the OPG+IL-8 exosomes+Eucommia ulmoides treatment group, except that the Eucommia ulmoides extract was replaced with an equal volume of water.

[0070] 6. OPG exosomes + Eucommia ulmoides treatment group (1) and (2) are the same as the OPG+IL-8 exosomes+Eucommia ulmoides treatment group, except that the mesenchymal stem cell exosomes used are mesenchymal stem cell exosomes that can express OPG protein.

[0071] 7. IL-8 exosomes + Eucommia ulmoides treatment group (1) and (2) are the same as the OPG+IL-8 exosomes+Eucommia ulmoides treatment group, except that the mesenchymal stem cell exosomes used are mesenchymal stem cell exosomes that can express IL-8 protein.

[0072] Each of the 7 treatment groups was further divided into two groups, high-dose and low-dose, i.e., each group had 5 mice. Five 4-week-old SPF-grade ovariectomized C57 mice (OPG- / -) were taken as the blank group, and five SPF-grade C57 mice were taken as the wild group.

[0073] Each nostril of the blank group and the wild group mice was given 15 μL of normal saline with a micropipette, which was considered as one administration; each nostril of the high-dose group of the treatment group was given 15 μL of the corresponding nasal spray, which was considered as one administration; each nostril of the low-dose group of the treatment group was given 5 μL of the corresponding nasal spray, which was considered as one administration. The drug was administered once in the morning, noon, and evening every day for two consecutive months. After the administration, the bilateral femurs and tibias of the mice were taken, wrapped with gauze soaked in normal saline, and stored at -20 ℃.

[0074] 2. Bone biomechanics measurement The mouse femur was taken out of the refrigerator, and after natural thawing, a three-point bending test was performed on the right femur using a microcomputer-controlled electronic universal testing machine. The full length of the right femur of the mouse was first measured with a vernier caliper, and the part with a distance of half the full length from the femoral head was defined as the midpoint of the femur. The femur was then placed in the middle of the three-point bending platform, and a vernier caliper was used to limit the span of the bracket to 10 mm, that is, the distance from both ends of the bracket to the midpoint of the femur was 5 mm. A downward lateral pressure was applied at a speed of 2 mm / min at the midpoint of the femur until the femur was destroyed, and the maximum bending load and maximum compressive stress of the femur were measured. The results were averaged, as shown in Table 1.

[0075] Table 1

[0076] visible: (1) Compared with the blank group and other treatment groups, the maximum bending load and maximum compressive stress of the OPG+IL-8 exosomes+Eucommia ulmoides treatment group were significantly increased, indicating that the present invention combines mesenchymal stem cell exosomes that can simultaneously express OPG protein and IL-8 protein with Eucommia ulmoides extract to obtain a composition that can significantly improve the bending resistance and compressive stress of bones, that is, improve the strength and toughness of bones, thereby effectively treating osteoporosis.

[0077] (2) Compared with the blank group, the maximum bending loads of the high-dose OPG exosomes, IL-8 exosomes, and Eucommia ulmoides treatment groups increased by 0.467, 0.092, and 0.046 N, respectively, while the high-dose OPG+IL-8 exosomes+Eucommia ulmoides treatment group increased by 1.042 N (>0.467+0.092+0.046=0.605), indicating that OPG protein, IL-8 protein, and Eucommia ulmoides extract have a significant synergistic effect in improving the bending resistance of bones.

[0078] (3) Compared with the blank group, the maximum bending loads of the low-dose OPG exosomes, IL-8 exosomes, and Eucommia ulmoides treatment groups increased by 0.347, 0.043, and 0.032 N, respectively, while the low-dose OPG+IL-8 exosomes+Eucommia ulmoides treatment group increased by 0.900 N (>0.347+0.043+0.032=0.422), indicating that OPG protein, IL-8 protein, and Eucommia ulmoides extract have a significant synergistic effect in improving the bending resistance of bones.

[0079] (4) Compared with the blank group, the maximum compressive stress of the high-dose OPG exosomes treatment group, IL-8 exosomes treatment group, and Eucommia ulmoides treatment group increased by 0.144, 0.070, and 0.012 MPa, respectively, while the maximum compressive stress of the high-dose OPG+IL-8 exosomes+Eucommia ulmoides treatment group increased by 0.477 MPa (>0.144+0.070+0.012=0.226), indicating that OPG protein, IL-8 protein, and Eucommia ulmoides extract have a significant synergistic effect in increasing bone compressive stress.

[0080] (5) Compared with the blank group, the maximum compressive stress of the low-dose OPG exosomes treatment group, IL-8 exosomes treatment group, and Eucommia ulmoides treatment group increased by 0.096, 0.035, and 0.009 MPa, respectively, while the low-dose OPG+IL-8 exosomes+Eucommia ulmoides treatment group increased by 0.449 MPa (>0.096+0.035+0.009=0.140), indicating that OPG protein, IL-8 protein, and Eucommia ulmoides extract have a significant synergistic effect in increasing bone compressive stress.

[0081] In summary, the composition of the present invention can significantly improve the bending resistance and compressive stress of bones, that is, it can significantly improve the strength and toughness of bones, thereby effectively treating osteoporosis, and OPG protein, IL-8 protein and Eucommia ulmoides extract have a significant synergistic effect in the treatment of osteoporosis.

[0082] 3. Bone density and tissue mineral density measurement The tibia of the right leg of the mouse was scanned using cone beam X-rays, and the bone mineral density (BMD) and tissue mineral density (TMD) were analyzed using vivaCT80 software. The results were averaged, as shown in Table 2.

[0083] Table 2

[0084] visible: (1) Compared with the blank group and other treatment groups, the bone density and tissue mineral density of the OPG+IL-8 exosomes+Eucommia ulmoides treatment group were significantly increased, indicating that the present invention combines mesenchymal stem cell exosomes that can simultaneously express OPG protein and IL-8 protein with Eucommia ulmoides extract to obtain a composition that can significantly increase bone density and tissue mineral density, that is, improve bone strength and toughness, thereby effectively treating osteoporosis.

[0085] (2) Compared with the blank group, the bone density of the low-dose OPG exosomes treatment group, IL-8 exosomes treatment group, and Eucommia ulmoides treatment group increased by 190.29, 71.95, and 12.83 mg HA / ccm, respectively, while the low-dose OPG+IL-8 exosomes+Eucommia ulmoides treatment group increased by 299.84 mg HA / ccm (>190.29+71.95+12.83=275.07), indicating that OPG protein, IL-8 protein, and Eucommia ulmoides extract have a significant synergistic effect in improving bone density.

[0086] (3) Compared with the blank group, the tissue mineral density of the high-dose OPG exosomes treatment group, IL-8 exosomes treatment group, and Eucommia ulmoides treatment group increased by 271.20, 92.27, and 34.12 mg HA / ccm, respectively, while the high-dose OPG+IL-8 exosomes+Eucommia ulmoides treatment group increased by 539.02 mg HA / ccm (>271.20+92.27+34.12=397.59), indicating that OPG protein, IL-8 protein, and Eucommia ulmoides extract have a significant synergistic effect in improving tissue mineral density.

[0087] (4) Compared with the blank group, the tissue mineral density of the low-dose OPG exosomes treatment group, IL-8 exosomes treatment group, and Eucommia ulmoides treatment group increased by 215.11, 69.06, and 7.63 mg HA / ccm, respectively, while the low-dose OPG+IL-8 exosomes+Eucommia ulmoides treatment group increased by 476.64 mg HA / ccm (>215.11+69.06+7.63=291.80), indicating that OPG protein, IL-8 protein, and Eucommia ulmoides extract have a significant synergistic effect in improving tissue mineral density.

[0088] In summary, the composition of the present invention can significantly increase bone density and tissue mineral density, that is, it can significantly improve bone strength, bone toughness and bone recovery ability, thereby effectively treating osteoporosis, and OPG protein, IL-8 protein and Eucommia ulmoides extract have a significant synergistic effect in the treatment of osteoporosis.

[0089] The above embodiments are preferred implementation modes of the present invention, but the implementation modes of the present invention are not limited to the above embodiments. Any other changes, modifications, substitutions, combinations, and simplifications that do not deviate from the spirit and principles of the present invention should be equivalent replacement methods and are included in the protection scope of the present invention.

Claims

1. A composition for treating osteoporosis, characterized in that: The invention contains mesenchymal stem cell exosomes and eucommia extract in a dosage ratio of 14-16 mg: 8-12 mL; the mesenchymal stem cell exosomes are mesenchymal stem cell exosomes that can simultaneously express OPG protein and IL-8 protein; the amino acid sequence of the OPG protein is shown in SEQ ID NO:1, and the amino acid sequence of the IL-8 protein is shown in SEQ ID NO:2; each 1 mL of eucommia extract contains an extract equivalent to 0.8-1.2 g of eucommia.

2. The composition according to claim 1, characterized in that The mesenchymal stem cells are umbilical cord mesenchymal stem cells.

3. The composition according to claim 1, characterized in that The preparation method of the eucommia extract is as follows: soak the eucommia in water for 10 to 14 hours, heat and extract at 95 to 100°C for 5.4 to 6.6 hours, filter, and concentrate the filtrate.

4. Use of the composition according to any one of claims 1 to 3 in the preparation of a medicament for treating osteoporosis.

5. A drug for treating osteoporosis, characterized in that: Each 1000 mL of the drug contains the following components: 14-16 mg of mesenchymal stem cell exosomes, 8-12 mL of Eucommia ulmoides extract, 25-35 g of detergent, 20-30 g of moisturizer, and the balance is water; The mesenchymal stem cell exosomes are mesenchymal stem cell exosomes that can simultaneously express OPG protein and IL-8 protein; each 1 mL of eucommia extract contains an extract equivalent to 0.8 to 1.2 g of eucommia.

6. The medicine according to claim 5, characterized in that Each 1000 mL of the drug contains the following components: 14-16 mg of mesenchymal stem cell exosomes, 8-12 mL of Eucommia ulmoides extract, 25-35 g of detergent, 8-10 g of preservative, 20-30 g of moisturizer, and the balance is water.

7. The medicine according to claim 5, characterized in that Each 1000 mL of the drug contains the following components: 14-16 mg of mesenchymal stem cell exosomes, 8-12 mL of Eucommia ulmoides extract, 25-35 g of detergent, 18-22 g of suspending agent, 20-30 g of moisturizer, and the balance is water.

8. The medicine according to claim 5, characterized in that Each 1000 mL of the drug contains the following components: 14-16 mg of mesenchymal stem cell exosomes, 8-12 mL of Eucommia ulmoides extract, 25-35 g of detergent, 20-30 g of moisturizer, 6-8 g of cooling agent, and the balance is water.

9. The drug according to claim 5, characterized in that: The cleaning agent is sodium chloride.

10. The drug according to claim 5, characterized in that: The humectant is glycerin.

Citation Information

Patent Citations

  • Application of mesenchymal stem cell exosome in preparation of osteoporosis prevention and treatment drug

    CN108478600A

  • Umbilical cord mesenchymal stem cells modified by NTF4 (neurotrophin 4) gene and construction method and application thereof

    CN108753730A

  • Composition of eucommia ulmoides extract and application of composition in preparation of anti-osteoporosis medicine

    CN115844941A

  • Anti-interleukin 8 therapy for tumor osteolysis

    US20050142136A1

  • Cartilage regeneration using combination of il-8 and bone marrow concentrate

    WO2018012736A1